Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 29, 2009

Celera Licenses Five Cancer-Related Targets to Bayer Schering Pharma

  • Bayer Schering Pharma has obtained access to five cancer-related targets from Celera for therapeutic development and in vivo diagnostic imaging. Celera retains in vitro diagnostic rights and will be able to develop and commercialize related companion diagnostics for candidates arising from Bayer Schering Pharma’s program.

    The therapeutic targets licensed under this exclusive agreement are reportedly over expressed on the surface of several different tumor cell types. They were found with Celera’s proteomics discovery platform.

    Bayer Schering Pharma will pay Celera an up-front fee, and additional payments are due upon achievement of certain development and commercial milestones. Upon commercialization of a product, Celera is entitled to royalties based on net sales.


    Related News
    Bayer Pays $4M Upfront to Use ImmunoGen’s Technology for a Solid Tumor Target (Oct. 21, 2008)
    Bayer Pays Ardea $35M for Its Anticancer MEK Inhibitors (Apr. 28, 2009)
    Merck & Co. In-Licenses Cancer Targets from Celera to Develop RNAi Drugs (Apr. 10, 2008)
    Celera Licenses Oncology-Related Discoveries to LabCorp (Apr. 25, 2007)

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »